These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21161615)

  • 61. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.
    Santra S; Liao HX; Zhang R; Muldoon M; Watson S; Fischer W; Theiler J; Szinger J; Balachandran H; Buzby A; Quinn D; Parks RJ; Tsao CY; Carville A; Mansfield KG; Pavlakis GN; Felber BK; Haynes BF; Korber BT; Letvin NL
    Nat Med; 2010 Mar; 16(3):324-8. PubMed ID: 20173754
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization.
    Dosenovic P; Chakrabarti B; Soldemo M; Douagi I; Forsell MN; Li Y; Phogat A; Paulie S; Hoxie J; Wyatt RT; Karlsson Hedestam GB
    J Immunol; 2009 Sep; 183(5):3373-82. PubMed ID: 19696434
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals.
    Kardava L; Moir S; Shah N; Wang W; Wilson R; Buckner CM; Santich BH; Kim LJ; Spurlin EE; Nelson AK; Wheatley AK; Harvey CJ; McDermott AB; Wucherpfennig KW; Chun TW; Tsang JS; Li Y; Fauci AS
    J Clin Invest; 2014 Jul; 124(7):3252-62. PubMed ID: 24892810
    [TBL] [Abstract][Full Text] [Related]  

  • 64. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination.
    Gahery H; Figueiredo S; Texier C; Pouvelle-Moratille S; Ourth L; Igea C; Surenaud M; Guillet JG; Maillere B
    AIDS Res Hum Retroviruses; 2007 Mar; 23(3):427-37. PubMed ID: 17411376
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes.
    Murakoshi H; Akahoshi T; Koyanagi M; Chikata T; Naruto T; Maruyama R; Tamura Y; Ishizuka N; Gatanaga H; Oka S; Takiguchi M
    J Virol; 2015 May; 89(10):5330-9. PubMed ID: 25741000
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity.
    Veillette M; Désormeaux A; Medjahed H; Gharsallah NE; Coutu M; Baalwa J; Guan Y; Lewis G; Ferrari G; Hahn BH; Haynes BF; Robinson JE; Kaufmann DE; Bonsignori M; Sodroski J; Finzi A
    J Virol; 2014 Mar; 88(5):2633-44. PubMed ID: 24352444
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure.
    Dekaban GA; Dikeakos JD
    AIDS Res Ther; 2017 Sep; 14(1):53. PubMed ID: 28893294
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.
    Lewis GK; DeVico AL; Gallo RC
    Proc Natl Acad Sci U S A; 2014 Nov; 111(44):15614-21. PubMed ID: 25349379
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine.
    Arrode G; Hegde R; Jin Y; Singh DK; Narayan O; Chebloune Y
    Vaccine; 2008 Jul; 26(31):3795-804. PubMed ID: 18586360
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Co-delivery of LIGHT expression plasmid enhances humoral and cellular immune responses to HIV-1 Nef in mice.
    Wen J; Hao W; Fan Y; Du J; Du B; Qian M; Jiang W
    Arch Virol; 2014 Jul; 159(7):1663-9. PubMed ID: 24435162
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.
    Wang L; Cheng C; Ko SY; Kong WP; Kanekiyo M; Einfeld D; Schwartz RM; King CR; Gall JG; Nabel GJ
    J Virol; 2009 Jul; 83(14):7166-75. PubMed ID: 19420074
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
    Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
    J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.
    Bresk CA; Hofer T; Wilmschen S; Krismer M; Beierfuß A; Effantin G; Weissenhorn W; Hogan MJ; Jordan APO; Gelman RS; Montefiori DC; Liao HX; Schmitz JE; Haynes BF; von Laer D; Kimpel J
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30769947
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm.
    Zhang X; Sobue T; Isshiki M; Makino S; Inoue M; Kato K; Shioda T; Ohashi T; Sato H; Komano J; Hanabusa H; Shida H
    PLoS One; 2012; 7(12):e51633. PubMed ID: 23236521
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lessons learned from HIV-1 vaccine trials: new priorities and directions.
    McMichael AJ; Haynes BF
    Nat Immunol; 2012 Apr; 13(5):423-7. PubMed ID: 22513323
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.
    Bellino S; Tripiciano A; Picconi O; Francavilla V; Longo O; Sgadari C; Paniccia G; Arancio A; Angarano G; Ladisa N; Lazzarin A; Tambussi G; Nozza S; Torti C; Focà E; Palamara G; Latini A; Sighinolfi L; Mazzotta F; Di Pietro M; Di Perri G; Bonora S; Mercurio VS; Mussini C; Gori A; Galli M; Monini P; Cafaro A; Ensoli F; Ensoli B
    Retrovirology; 2014 Jun; 11():49. PubMed ID: 24961156
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity.
    Alsahafi N; Ding S; Richard J; Markle T; Brassard N; Walker B; Lewis GK; Kaufmann DE; Brockman MA; Finzi A
    J Virol; 2015 Dec; 90(6):2993-3002. PubMed ID: 26719277
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial.
    Campion SL; Brenna E; Thomson E; Fischer W; Ladell K; McLaren JE; Price DA; Frahm N; McElrath JM; Cohen KW; Maenza JR; Walsh SR; Baden LR; Haynes BF; Korber B; Borrow P; McMichael AJ
    J Clin Invest; 2021 Dec; 131(23):. PubMed ID: 34850742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.